Relmada Therapeutics

Contributing Author

Recent Articles by Relmada Therapeutics

Aug-06	Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update RLMD RLMD -8.01% GlobeNewswire
Jul-28	Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer RLMD GlobeNewswire
Jul-16	Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 RLMD -12.08% GlobeNewswire
Jun-29	Relmada Therapeutics Joins Russell 2000 and Russell 3000 Indexes RLMD GlobeNewswire
Jun-11	Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program RLMD GlobeNewswire
May-28	Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference RLMD GlobeNewswire
May-12	Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update RLMD GlobeNewswire
May-06	Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 RLMD +6.94% GlobeNewswire
May-05	Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 RLMD GlobeNewswire
Mar-19	Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update RLMD GlobeNewswire
Mar-12	Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 RLMD GlobeNewswire
Mar-09	Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference RLMD +61.12% RLMD -7.67% GlobeNewswire
Mar-09	Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing RLMD +61.12% GlobeNewswire
Mar-09	Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer RLMD +61.12% GlobeNewswire
Jan-12	Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications RLMD GlobeNewswire
Dec-03	Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology RLMD GlobeNewswire
Nov-13	Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates RLMD GlobeNewswire
Nov-07	Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 RLMD GlobeNewswire
Nov-04	Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants RLMD +25.91% GlobeNewswire
Nov-04	Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer RLMD +25.91% GlobeNewswire
Oct-07	Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 RLMD GlobeNewswire
Sep-16	Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement RLMD GlobeNewswire
Sep-10	Relmada Issues Mid-Year CEO Letter to Shareholders RLMD GlobeNewswire
Aug-07	Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC RLMD GlobeNewswire
Jul-31	Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 RLMD GlobeNewswire
Jul-15	Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 RLMD GlobeNewswire
Jun-17	Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology RLMD GlobeNewswire
May-12	Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update RLMD -5.05% GlobeNewswire
May-08	Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 RLMD +5.64% GlobeNewswire

Relmada Therapeutics

Recent Articles by Relmada Therapeutics

Upgrade your Finviz experience